

ANZGOG Preceptorship in Ovarian Cancer 2021

Virtual 2-Day Education Event | Program



The Preceptorship in Ovarian Cancer is supported by



DAY 1 – Friday, 3 December | 12.30pm – 5.30pm AEDT

12.30pm-12.40pm	10 mins	WELCOME - <i>Tarek Meniawy</i>
12.40pm-1.50pm	70 mins	<p>PRECEPTORS Alison Brand Paul Cohen Orla McNally Bryony Simcock</p> <p>SURGERY</p> <ol style="list-style-type: none"> 1. What is the role of ultra radical surgery (including but not limited to HIPEC) in the management of newly diagnosed ovarian cancer, including ongoing trials? – <i>Leon Foster</i> 2. Why are clinical quality indicators important in the surgical (and medical) management of ovarian cancer? – <i>Omali Pitiyarachchi</i> <p style="text-align: center;">5 min Q&A</p> <ol style="list-style-type: none"> 3. Discuss the evidence for optimisation of perioperative care for patients being considered for surgical management of advanced ovarian cancer? – <i>Sathya Manoharan</i> 4. What is the role of lymph node dissection in early and advanced ovarian cancer? – <i>Tharani Krishnan</i> <p style="text-align: center;">5 min Q&A</p> <ol style="list-style-type: none"> 5. What is the evidence for the use of laparoscopy in the management of ovarian cancer? (5min) – <i>Sandy Simon</i> 6. Is hormone replacement therapy safe in women rendered menopausal by ovarian cancer treatment? (5min) – <i>Sarah Williams</i> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>
1.50pm-2.25pm	35 mins	<p>PRECEPTORS Viet Do Pearly Khaw</p> <p>RADIATION AND ITS ROLE IN TREATING OVARIAN CANCER</p> <ol style="list-style-type: none"> 1. Role of radiotherapy in adjuvant treatment of ovarian cancer. Why omit Radiation Therapy from the treatment paradigm? Have we been misled by chemotherapy and immunotherapy outcomes and forgotten the usefulness of this modality? – <i>Nicole Pringle</i> <p style="text-align: center;">5 min Q&A</p> <ol style="list-style-type: none"> 2. What is the role of radiotherapy in recurrent or palliative treatment of ovarian cancer? Explore the role of stereotactic ablative RT in allowing patients to have a “drug holiday” in between lines of chemotherapy. (5min) – <i>Nadia Ghazali</i> 3. Which histology subgroups should we offer radiotherapy to? (5min) – <i>Mark Flower</i> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>

2.25pm-2.30pm	5 mins	BREAK
2.30pm-3.40pm PRECEPTORS Connie Diakos Michelle Harrison Yeh Chen Lee Felicia Roncolato Michelle Wilson Alison Davis	70 mins	CHEMOTHERAPY 1ST LINE 1. Carboplatin and Paclitaxel is the standard chemotherapy for 1st line ovarian cancer? Do we take into account histology, stage, ethnicity and frailty? Route of administration and scheduling. – <i>Sandy Simon</i> 2. How do we decide on upfront surgery vs neo-adjuvant chemotherapy? – <i>Sara Yeoh</i> <p style="text-align: center;">5 min Q&A</p> 3. Should everyone receive a PARP inhibitor as maintenance therapy? Should this be alone or in combination with Bevacizumab? – <i>Marilyn Boo</i> 4. Should patients receive Bevacizumab and/or Immunotherapy in 1st line ovarian cancer? Which patients should receive Bevacizumab and/or Immunotherapy in 1st line ovarian cancer and for how long? – <i>Nicole Krzys</i> <p style="text-align: center;">5 min Q&A</p> 5. How do we follow these women up and help them improve survivorship? – <i>Sarah Te Whaiti</i> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>
3.40pm-4.25pm PRECEPTORS David Bowtell Kathryn Alsop Dale Garsed	45 mins	GENETICS AND MOLECULAR PATHOLOGY 1. What is known about the molecular features of primary and acquired drug resistance in high grade serous ovarian cancer? – <i>Navin David</i> 2. In what circumstances should BRCA and panel testing be requested for a patient? (5min) – <i>Mark Flower</i> <p style="text-align: center;">5 min Q&A</p> 3. What implications does a germline mutation diagnosis have for patients and their family members? (5min) – <i>Tivya Kulasegaran</i> 4. What is Homologous Recombination Deficiency (HRD) and how should you test for HRD status? – <i>Reece Caldwell</i> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>
4.25pm-5.00pm PRECEPTORS Lyndal Anderson Raghwa Sharma	35 mins	PATHOLOGY OF OVARIAN CANCERS 1. How do we produce a chemotherapy response score (CRS)? (5min) – <i>Amy Davies</i> 2. What are the ovarian sex cord-stromal tumours? (5min) – <i>Nadia Hitchen</i> <p style="text-align: center;">5 min Q&A</p>

		<p>3. What types of malignant transformation happen in ovarian teratomas? (5min) – <i>Tivya Kulasegaran</i></p> <p>4. Where do neuroendocrine tumour fit into the classification of ovarian cancers? How many types are there? (5min) – <i>Nadia Hitchen</i></p> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>
5.00pm-5.10pm	10 mins	CLOSING REMARKS – <i>Tarek Meniawy</i>

DAY 2 – Saturday, 4 December | 10.00am – 12.00pm AEDT

10.00am-10.10am	10 mins	WELCOME – <i>Sally Baron-Hay</i>
10.10am-10.30am	20 mins	<p>"How to get involved with ANZGOG clinical trials – mentoring new researchers"</p> <p>- <i>Dr Alison Davis, Chair Research Advisory Committee & Ms Wanda Lawson, Chair Consumer Research Panel</i></p> <p style="text-align: center;">5 min Q&A</p>
10.30am-11.50am	80 mins	<p>RECURRENT OVARIAN CANCER</p> <p>PRECEPTORS Connie Diakos Michelle Harrison Yeh Chen Lee Michelle Wilson Alison Davis</p> <p>1. Who should undergo secondary debulking? – <i>Danka Zebic</i></p> <p>2. Chemotherapy options for platinum sensitive ovarian cancer? What is the best sequence? – <i>Silipa Naiqiso</i></p> <p style="text-align: center;">5 min Q&A</p> <p>3. What is the role of PARPi in recurrent ovarian cancer? When, what, and can we rechallenge? – <i>Gaithri Mylvaganam</i></p> <p>4. How do we best use Bevacizumab in recurrent ovarian cancer? When, how, and can we rechallenge? – <i>Monica McGauran</i></p> <p style="text-align: center;">5 min Q&A</p> <p>5. Decision making tool in platinum-resistant / refractory ovarian cancer? Chemotherapy vs best supportive care? – <i>Betty Zhang</i></p> <p>6. How should we best measure QOL in ovarian cancer? How do we ensure we make people live better with our treatments? – <i>Chloe Georgiou</i></p> <p style="text-align: center;">10 min Panel Discussion with Preceptors</p>
11.50am-12.00pm	10 mins	CLOSING REMARKS – <i>Michelle Wilson & Sally Baron-Hay</i>

Our thanks to GSK for supporting this Preceptorship in Ovarian Cancer.

